While in most cancers PK/TF fusions made up around 20–25% of all protein producing OFs, the percentage reached 60% in acute myeloid leukemia (LAML) samples , 46% in thymoma (THYM), 45% in thyroid carcinoma (THCA), and 37% and 36% in kidney renal papillary cell carcinoma (KIRP) and cholangiocarcinoma (CHOL) respectively (Fig. 1C). This evidence concerns the gene TF and cholangiocarcinoma.